Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

AstraZeneca’s Calquence impresses in previously untreated CLL

Takes the fight to AbbVie/J&J’s Imbruvica

- PMLiVE

Bluebird bio’s sickle cell gene therapy shows early-study benefit

Closely follows approval of beta thalassaemia therapy Zynteglo

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

- PMLiVE

The 2019 CPhI Pharma Index Report

Examining this year’s industry performance

- PMLiVE

Sangamo steps up BioMarin chase with haemophilia gene therapy data

Updated results presented at ASH 2019

- PMLiVE

PharmaLex announces joint venture with Vintura

Partnership provides benefits for both organisations

- PMLiVE

Five key trends in precision and personalised healthcare

Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...

Blue Latitude Health

- PMLiVE

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

Met key primary and secondary trial endpoints

- PMLiVE

Biogen defends aducanumab filing plan amid scepticism

A new look at pivotal trial data described as hard-to-interpret

- PMLiVE

Novartis strengthens case for its combination asthma drug

Demonstrated significant benefits in uncontrolled asthma patients

OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications

Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications

OPEN Health

- PMLiVE

Sage slides off a MOUNTAIN as depression drug flunks trial

Share price drops 60% as investors react to news

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links